As­traZeneca’s Su­san Gal­braith high­lights twin wins for the can­cer drug pipeline at SABCS, as oral SERD ex­cels

It’s a good time to be the head of R&D for on­col­o­gy at As­traZeneca. And no one gets that quite like Su­san Gal­braith.

To­day, Gal­braith is at the San An­to­nio Breast Can­cer Sym­po­sium, high­light­ing the da­ta on two key drugs in the can­cer pipeline: mid-stage re­sults for its oral SERD camizes­trant among pa­tients af­ter one line of ther­a­py, and the AKT drug capi­vasert­ib, wrap­ping the Phase III. Both fall neat­ly in­to the range of suc­cess­es, beat­ing out ful­ves­trant in hor­mone re­cep­tor-pos­i­tive, HER2-neg­a­tive breast can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER